Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Douglas Faries

Showing results (21-30 of 41) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Psychiatry|February 5, 2009
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Pharmaceutical Statistics|January 22, 2014
Bayesian modeling of cost-effectiveness studies with unmeasured confounding: a simulation studyJames D Stamey, Daniel P Beavers, Douglas Faries, et al.
Psychiatric Services (Washington, D.C.)|March 1, 2008
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaBaojin Zhu, Haya Ascher-Svanum, Lizheng Shi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetesDouglas Faries, Xiaomei Peng, Manjiri Pawaskar, et al.
Psychiatric Services (Washington, D.C.)|April 7, 2007
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaLizheng Shi, Haya Ascher-Svanum, Baojin Zhu, et al.
Journal of Comparative Effectiveness Research|June 28, 2014
Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness researchCynthia J Girman, Douglas Faries, Patrick Ryan, et al.
BMC Medical Research Methodology|September 15, 2012
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trialDouglas Faries, Haya Ascher-Svanum, Glenn Phillips, et al.
Psychosomatics|January 18, 2015
The importance of unresolved fatigue in depression: costs and comorbiditiesRebecca L Robinson, Judith J Stephenson, Ellen B Dennehy, et al.
Clinical Pharmacology and Therapeutics|April 18, 2020
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines InitiativeMichael Happich, Alan Brnabic, Douglas Faries, et al.
Pharmaceutical Statistics|December 4, 2024
Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured ConfoundingDouglas Faries, Chenyin Gao, Xiang Zhang, et al.
Pageof 5

Showing results (21-30 of 41) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Psychiatry|February 5, 2009
Tardive dyskinesia and the 3-year course of schizophrenia: results from a large, prospective, naturalistic studyHaya Ascher-Svanum, Baojin Zhu, Douglas Faries, et al.
Pharmaceutical Statistics|January 22, 2014
Bayesian modeling of cost-effectiveness studies with unmeasured confounding: a simulation studyJames D Stamey, Daniel P Beavers, Douglas Faries, et al.
Psychiatric Services (Washington, D.C.)|March 1, 2008
Time to discontinuation of depot and oral first-generation antipsychotics in the usual care of schizophreniaBaojin Zhu, Haya Ascher-Svanum, Lizheng Shi, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|March 30, 2013
Evaluating the impact of unmeasured confounding with internal validation data: an example cost evaluation in type 2 diabetesDouglas Faries, Xiaomei Peng, Manjiri Pawaskar, et al.
Psychiatric Services (Washington, D.C.)|April 7, 2007
Characteristics and use patterns of patients taking first-generation depot antipsychotics or oral antipsychotics for schizophreniaLizheng Shi, Haya Ascher-Svanum, Baojin Zhu, et al.
Journal of Comparative Effectiveness Research|June 28, 2014
Pre-study feasibility and identifying sensitivity analyses for protocol pre-specification in comparative effectiveness researchCynthia J Girman, Douglas Faries, Patrick Ryan, et al.
BMC Medical Research Methodology|September 15, 2012
Construct validity of 2 measures to assess reasons for antipsychotic discontinuation and continuation from patients' and clinicians' perspectives in a clinical trialDouglas Faries, Haya Ascher-Svanum, Glenn Phillips, et al.
Psychosomatics|January 18, 2015
The importance of unresolved fatigue in depression: costs and comorbiditiesRebecca L Robinson, Judith J Stephenson, Ellen B Dennehy, et al.
Clinical Pharmacology and Therapeutics|April 18, 2020
Reweighting Randomized Controlled Trial Evidence to Better Reflect Real Life - A Case Study of the Innovative Medicines InitiativeMichael Happich, Alan Brnabic, Douglas Faries, et al.
Pharmaceutical Statistics|December 4, 2024
Real Effect or Bias? Good Practices for Evaluating the Robustness of Evidence From Comparative Observational Studies Through Quantitative Sensitivity Analysis for Unmeasured ConfoundingDouglas Faries, Chenyin Gao, Xiang Zhang, et al.
Pageof 5